Eloxx Q1 net loss $11.6M; CF award up to $15.9M; cash into Q2 2023

Eloxx Pharmaceuticals, Inc.

2023-Q1 EPS reported -$5.36 vs consensus -$28.61 ▲ beat (+81.3%)

Net loss $11.6M ($0.13/sh) vs $8.7M ($0.22/sh) in Q1 2021; R&D $7.9M, G&A $3.1M.
CF Foundation award up to $15.9M for ELX-02; Phase 2 CF topline results expected end H1 2022.
Expanded ELX-02 development to Alport syndrome; Phase 2 proof-of-concept trial for nonsense mutations starts H2 2022.
Cash $39.8M sufficient into Q2 2023; ZKN-013 IND for RDEB planned H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.